GERON CORP
Close on Oct 19, 2026
- Market cap
- $804.84K
- P/E (TTM)
- –
- Dividend yield
- –
About Geron
Pharmaceutical Preparations, SIC 2834
Geron Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutics for hematologic malignancies. Its primary product is RYTELO (imetelstat), an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. In addition to commercializing RYTELO, the company conducts clinical research and development, including advanced clinical trials such as the IMpactMF Phase 3 study evaluating imetelstat in patients with relapsed or refractory myelofibrosis. Geron's operations serve eligible patients, healthcare providers, and clinical trial participants across specialized oncology care.
The company conducts commercial activities and clinical programs in the United States and works to expand the availability of its therapies internationally, including within the European Union. Geron operates through wholly owned subsidiaries located in the United Kingdom and the Netherlands. The company maintains its corporate headquarters and principal executive offices in Foster City, California, alongside leased office facilities in New Jersey.
Summary of the business section of Geron's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GERON CORP
- Founded
- 1990
- Headquarters
- Foster City, CA
- Address
- 919 East Hillsdale Boulevard, Suite 250 94404
- Phone
- (650) 473-7700
- Website
- www.geron.com
- Employees
- 42, Dec 31, 2014
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- GERN
- Exchange
- Nasdaq
- IPO date
- Jul 31, 1996
- Shares outstanding
- 642M, Jul 31, 2026
- Public float
- $860.50M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 886744
- CUSIP
- 374163103
- ISIN
- US3741631036
- LEI
- 549300T282D7Z2YESL90
- EIN
- 75-2287752
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Harout Semerjian | President and CEO, Director | – |
| John A. Scarlett | Chairman, President and CEO, Director | 137,500 |
| Timothy Williams | EVP and Chief Legal Officer | – |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | 27,500 |
| Joseph Eid | EVP, R&D; Chief Medical Office | – |
| Ahmed ElNawawi | EVP, Chief Commercial Officer | 10,000 |
| James Ziegler | EVP, Chief Commercial Officer | 100,000 |
| Scott Alan Samuels | EVP, Chief Legal Officer | 26,682 |
| Andrew J. Grethlein | EVP, Chief Operating Officer | 676,615 |
| Robert J. Spiegel | Director | 205,810 |
| Dawn Carter Bir | Director | – |
| Elizabeth G. O'Farrell | Director | 33,627 |
| Susan Molineaux | Director | 165,527 |
| John F. McDonald | Director | – |
| Constantine Chinoporos | Director | – |
| Patricia S. Andrews | Director | – |
| V. Bryan Lawlis | Director | 13,300 |
| Gaurav Aggarwal | Director | 1,970 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dawn Bir | $522.12K | $243.25K | $2.37M | $83 | $125 |
| FY2025 Harout Semerjian | $10.22M | $10.18M | $2.37M | $83 | $125 |
| FY2025 John Scarlett | $7.42M | -$7.33M | $2.37M | $83 | $125 |
| FY2024 John Scarlett | $6.15M | $15.29M | $4.66M | $223 | $93 |
| FY2023 John Scarlett | $4.95M | $4.47M | $2.85M | $133 | $94 |
| FY2022 John Scarlett | $3.00M | $5.90M | $1.36M | $152 | $90 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2014, we had 42 employees, of whom 7 hold Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 7, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 8, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 1, 2013 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 12, 2009 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 5, 2005 | Name change | Name changed from GERON CORPORATION to GERON CORP |
| Jul 31, 1996 | IPO | Initial public offering priced (424B4 prospectus) |